Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 28, 2018; 24(8): 917-928
Published online Feb 28, 2018. doi: 10.3748/wjg.v24.i8.917
Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection
Yi-Chun Chen, Chung-Yi Li, Shiang-Jiun Tsai, Yen-Chun Chen
Yi-Chun Chen, Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi County 622, Taiwan
Yi-Chun Chen, School of Medicine, Tzu Chi University, Hualien 970, Taiwan
Chung-Yi Li, Department and Graduate Institute of Public Health, College of Medicine, National Cheng Hung University, Tainan 701, Taiwan
Chung-Yi Li, Department of Public Health, College of Public Health, China Medical University, Taichung 404, Taiwan
Shiang-Jiun Tsai, Department of Medical Research, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi County 622, Taiwan
Yen-Chun Chen, Division of Hepato-Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi County 622, Taiwan
Author contributions: Chen YC designed the research; Chen YC, Li CY and Tsai SJ performed the research; Chen YC, Li CY, Tsai SJ and Chen YC analyzed the data; Chen YC wrote the paper; Li CY, Tsai SJ, Chen YC critically revised the manuscript for important intellectual content.
Supported by Dalin Tzu Chi Hospital, No. DTCRD 104-I-16.
Institutional review board statement: This study was approved by the institutional review board of the Dalin Tzu Chi Hospital (B10302011).
Informed consent statement: All patients’ information was de-identified in the database (LHID2005) and no informed consent was required. This study was exempt from a full ethical review by the institutional review board of the Dalin Tzu Chi Hospital (B10302011).
Conflict-of-interest statement: All authors have no conflict of interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yi-Chun Chen, MD, Assistant Professor, Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Minsheng Road, Dalin Township, Chiayi County 622, Taiwan.
chenyichun0320@yahoo.com.tw
Telephone: +886-5-2648000-5665 Fax: +886-5-2648128
Received: November 4, 2017
Peer-review started: November 4, 2017
First decision: November 22, 2017
Revised: December 10, 2017
Accepted: December 20, 2017
Article in press: December 20, 2017
Published online: February 28, 2018
Processing time: 114 Days and 21 Hours
AIM
To investigate the risk of end-stage renal disease (ESRD) in hepatitis B virus (HBV)-infected patients with chronic kidney disease (CKD) with and without nucleos(t)ide analogue (NA) therapy.
METHODS
This nationwide cohort study included 103444 Taiwanese CKD adults without hepatitis C virus infection from the Taiwan Longitudinal Health Insurance Database 2005 between 1997 and 2012. We identified 2916 CKD patients who acquired HBV infection and did not receive NAs (untreated cohort), and they were propensity-matched 1:4 with 11664 uninfected counterparts. We also identified 442 CKD patients who acquired HBV infection and received NAs (treated cohort), and they were propensity-matched 1:3 with 1326 untreated counterparts. The association between HBV infection, NA use, and ESRD was analyzed using competing risk analysis.
RESULTS
Multivariable Cox regression analysis showed a 1.67-fold higher risk (P < 0.0001) of ESRD in the untreated cohort (16-year cumulative incidence, 10.1%) than in the matched uninfected cohort (16-year cumulative incidence, 6.6%), which was independent of cirrhosis or diabetes. The treated cohort (16-year cumulative incidence, 2.2%) had an 87% lower ESRD risk (P < 0.0001) compared with the matched untreated cohort (16-year cumulative incidence, 11.9%). The number needed to treat for one fewer ESRD after NA use at 12 years was 12. Multivariable stratified analyses verified these associations in all subgroups.
CONCLUSION
This study suggests that untreated HBV infection and NA therapy are associated with increased and decreased risk of ESRD, respectively, in CKD patients. Identification of HBV status and targeted monitoring for ESRD development are important in CKD patients living in HBV-endemic areas.
Core tip: This nationwide retrospective cohort study used propensity score-matched and competing risk analyses to evaluate the effect of untreated hepatitis B virus (HBV) infection and nucleos(t)ide analogue (NA) therapy on the development of end-stage renal disease (ESRD) in chronic kidney disease (CKD) patients who acquired HBV infection. We found that untreated HBV infection in CKD patients was associated with an increased risk of ESRD, while NA therapy reduced the risk.
